Last edition
News about "Advanced Solid Tumors and Hematological Malignanci"
Transcenta Holding Limited, a global biotherapeutics company announced that the updated phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been presented as an abstract online publication
Advanced Solid Tumors And Hematological Malignanci | 21/05/2021 | By Darshana | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members